Quantify the ability of the human hand to perform independent movements
Completed
- Conditions
- Duchenne Muscular Dystrophy/ Duchenne Disease10029317
- Registration Number
- NL-OMON45540
- Lead Sponsor
- niversiteit Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
-Age: 18-28 years
-Affected hand function
Exclusion Criteria
-Above or below the age band allowed (18-28)
-Epileptic seizure history
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the amount of information in bits/sec people convey<br /><br>through their hands. This can change depending on the amount of stimuli, and<br /><br>their presentation rate (frequency). Also, the workload every condition imposes<br /><br>on the subject is assessed via a questionnaire.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary study parameter is the capability of sEMG on the forearm of<br /><br>people with DMD to provide the necessary information to recognize different<br /><br>gestures. Additionally, the difference between healthy people and people with<br /><br>DMD will be evaluated.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie dystrophin deficiency's impact on hand motor function in Duchenne Muscular Dystrophy?
How does the non-invasive hand movement quantification in NL-OMON45540 compare to standard corticosteroid efficacy measures in DMD?
Which neuromuscular biomarkers are associated with independent hand movement preservation in DMD patients?
What adverse events are reported in DMD observational trials using motion capture technology, and how are they managed?
How might findings from NL-OMON45540 influence the development of gene therapy or exon-skipping treatments for DMD?